Cargando…

Advances in clinical basic research: Performance, treatments, and mechanisms of Parkinson disease

The loss of neuronal in the substantia nigra of the elderly contributes to striatal damage and plays a critical part in the common forms of neurodegenerative diseases such as Parkinson disease (PD). The deficit of dopamine is one of the most familiar neuropathological features of PD as well as α‐Syn...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Ting‐Ting, Liu, Yu‐Cong, Li, Jing, Xu, Hui‐Chan, Li, Shun‐Lian, Xiong, Liu‐Lin, Wang, Ting‐Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10529016/
https://www.ncbi.nlm.nih.gov/pubmed/37786563
http://dx.doi.org/10.1002/ibra.12011
_version_ 1785111336285372416
author Yang, Ting‐Ting
Liu, Yu‐Cong
Li, Jing
Xu, Hui‐Chan
Li, Shun‐Lian
Xiong, Liu‐Lin
Wang, Ting‐Hua
author_facet Yang, Ting‐Ting
Liu, Yu‐Cong
Li, Jing
Xu, Hui‐Chan
Li, Shun‐Lian
Xiong, Liu‐Lin
Wang, Ting‐Hua
author_sort Yang, Ting‐Ting
collection PubMed
description The loss of neuronal in the substantia nigra of the elderly contributes to striatal damage and plays a critical part in the common forms of neurodegenerative diseases such as Parkinson disease (PD). The deficit of dopamine is one of the most familiar neuropathological features of PD as well as α‐Synuclein aggregation. The peripheral autonomic nervous system is also affected negatively during the course of the disease, although the subsistent of dyskinesias and else major motor characteristic deficits take significant role in the diagnostic methods during clinical practice, which is related to a number of non‐motor symptoms that might increase aggregate risks. Multiple pathways and mechanisms are involved in the molecular pathogenesis: α‐Synuclein, neuronal homeostasis, mitochondrial function, oxidative stress, as well as neuroinflammation. Investigations in the last few years for diagnostic biomarkers used neuroimaging, including single photon emission computed tomography  as well as cutting‐edge magnetic resonance imaging techniques, which has been presented to facilitate discrepant diagnosis. Pharmacological treatment is also important and efficient in equal measure. In addition to reliance on striatal dopamine replacement therapy, many solutions that are used for motor or nonmotor symptoms in these patients are available.
format Online
Article
Text
id pubmed-10529016
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-105290162023-10-02 Advances in clinical basic research: Performance, treatments, and mechanisms of Parkinson disease Yang, Ting‐Ting Liu, Yu‐Cong Li, Jing Xu, Hui‐Chan Li, Shun‐Lian Xiong, Liu‐Lin Wang, Ting‐Hua Ibrain Reviews The loss of neuronal in the substantia nigra of the elderly contributes to striatal damage and plays a critical part in the common forms of neurodegenerative diseases such as Parkinson disease (PD). The deficit of dopamine is one of the most familiar neuropathological features of PD as well as α‐Synuclein aggregation. The peripheral autonomic nervous system is also affected negatively during the course of the disease, although the subsistent of dyskinesias and else major motor characteristic deficits take significant role in the diagnostic methods during clinical practice, which is related to a number of non‐motor symptoms that might increase aggregate risks. Multiple pathways and mechanisms are involved in the molecular pathogenesis: α‐Synuclein, neuronal homeostasis, mitochondrial function, oxidative stress, as well as neuroinflammation. Investigations in the last few years for diagnostic biomarkers used neuroimaging, including single photon emission computed tomography  as well as cutting‐edge magnetic resonance imaging techniques, which has been presented to facilitate discrepant diagnosis. Pharmacological treatment is also important and efficient in equal measure. In addition to reliance on striatal dopamine replacement therapy, many solutions that are used for motor or nonmotor symptoms in these patients are available. John Wiley and Sons Inc. 2021-12-23 /pmc/articles/PMC10529016/ /pubmed/37786563 http://dx.doi.org/10.1002/ibra.12011 Text en © 2021 The Authors. Ibrain published by Affiliated Hospital of Zunyi Medical University (AHZMU) and Wiley-VCH GmbH. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Reviews
Yang, Ting‐Ting
Liu, Yu‐Cong
Li, Jing
Xu, Hui‐Chan
Li, Shun‐Lian
Xiong, Liu‐Lin
Wang, Ting‐Hua
Advances in clinical basic research: Performance, treatments, and mechanisms of Parkinson disease
title Advances in clinical basic research: Performance, treatments, and mechanisms of Parkinson disease
title_full Advances in clinical basic research: Performance, treatments, and mechanisms of Parkinson disease
title_fullStr Advances in clinical basic research: Performance, treatments, and mechanisms of Parkinson disease
title_full_unstemmed Advances in clinical basic research: Performance, treatments, and mechanisms of Parkinson disease
title_short Advances in clinical basic research: Performance, treatments, and mechanisms of Parkinson disease
title_sort advances in clinical basic research: performance, treatments, and mechanisms of parkinson disease
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10529016/
https://www.ncbi.nlm.nih.gov/pubmed/37786563
http://dx.doi.org/10.1002/ibra.12011
work_keys_str_mv AT yangtingting advancesinclinicalbasicresearchperformancetreatmentsandmechanismsofparkinsondisease
AT liuyucong advancesinclinicalbasicresearchperformancetreatmentsandmechanismsofparkinsondisease
AT lijing advancesinclinicalbasicresearchperformancetreatmentsandmechanismsofparkinsondisease
AT xuhuichan advancesinclinicalbasicresearchperformancetreatmentsandmechanismsofparkinsondisease
AT lishunlian advancesinclinicalbasicresearchperformancetreatmentsandmechanismsofparkinsondisease
AT xiongliulin advancesinclinicalbasicresearchperformancetreatmentsandmechanismsofparkinsondisease
AT wangtinghua advancesinclinicalbasicresearchperformancetreatmentsandmechanismsofparkinsondisease